Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH2 | P48735 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.38 |
| ▸ | CCNK | O75909 | 2/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.38 |
| ▸ | CDK9 | P50750 | 2/20 | 0.38 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.36 |
| ▸ | FLT3 | P36888 | 4/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16286108 | 0.90 | TDP1 (0.41) | TDP1MKNK1MKNK2 | |
| SCHEMBL16286149 | 0.87 | IDH2 (0.38) | IDH2DPP4IRAK4CCNT1CCNK | |
| SCHEMBL16286123 | 0.85 | TRPV1 (0.38) | PTK2TDP1KMT2A | |
| SCHEMBL16286130 | 0.84 | C5AR1 (0.41) | DPP4PTK2TDP1 | |
| SCHEMBL10246368 | 0.83 | CDK4 (0.47) | CCNT1CCNKCCNE1CDK2CDK9 | |
| SCHEMBL16286110 | 0.80 | TDP1 (0.42) | TDP1MKNK1MKNK2 | |
| SCHEMBL16286112 | 0.80 | PTK2 (0.45) | CCNE1CDK2PTK2TDP1 | |
| SCHEMBL16286129 | 0.76 | TDP1 (0.40) | CCNE1CDK2PTK2TDP1 | |
| SCHEMBL10246428 | 0.75 | WEE1 (0.44) | CCNT1CCNKCCNE1CDK2CDK9 | |
| SCHEMBL16286126 | 0.74 | CDK4 (0.44) | CCNT1CDK9PTK2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | GRIN2A, GRIN2C, GRIN3A | IDH2 1067/4885DPP4 2692/4885IRAK4 3522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.